TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10470636

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (10 mg of hyperbaric tetracaine intrathecally)
Number of subjects: 21

Group type: COMPARATOR
Intervention: General Anesthesia (fentanyl i.v. 1 to 2 micrograms/kg, propofol i.v. 1.0 to 2.0 mg/kg, isoflurane end-tidal 0.7% to 1.2%, 70% nitrous oxide in oxygen)
Number of subjects: 21
Study: 9110278

Group type: EXPERIMENTAL
Intervention: Acceleration plethysmography (APG)
Number of subjects: 390
Study: 1765033

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking and jogging at a prescribed exercise intensity)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-aerobic strength and flexibility training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic exercise and Non-aerobic strength and flexibility training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study: 7085070

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 20
Study: 31855259

Group type: EXPERIMENTAL
Intervention: Idelalisib (IDEL) for relapsed follicular lymphoma (FL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Idelalisib (IDEL) with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL)
Number of subjects: 26
Study: 30716781

Group type: EXPERIMENTAL
Intervention: SED-ACT (interrupting sedentary time with high-intensity physical activity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HIIE (high-intensity interval exercise session)
Number of subjects: 12

Group type: COMPARATOR
Intervention: SED (prolonged uninterrupted sedentary time)
Number of subjects: 12
Study: 28364511

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Active Behavioral Desensitization Control (BD)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Active Behavioral Desensitization Control (BD)
Number of subjects: 74
Study: 26796052

Group type: EXPERIMENTAL
Intervention: Nordic treadmill training (NTT) for 30 minutes each day, 5 times per week for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treadmill training (TT) for 30 minutes each day, 5 times per week for 6 weeks
Number of subjects: 30
Study: 24508531

Group type: EXPERIMENTAL
Intervention: Postural rehabilitation (PR) for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to trunk muscles in 6 subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 22075488

Group type: EXPERIMENTAL
Intervention: Web-based application with educational material and remote expert support (PCi)
Number of subjects: 4581

Group type: COMPARATOR
Intervention: Control group with no access to web-based application (PCc)
Number of subjects: 4581
Study: 19092728

Group type: EXPERIMENTAL
Intervention: Polypoidal choroidal vasculopathy (PCV)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Central serous chorioretinopathy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Occult choroidal neovascularization secondary to age‐related macular degeneration
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Harada disease
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Retinal macroaneurysms
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diagnosis establishment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PCV in patients aged 60 and older
Number of subjects: 71
Study: 17251875

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg bolus followed by 8.3 mg/kg/hr infusion for 24 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (equivolume)
Number of subjects: 6
Study: 15835374

Group type: EXPERIMENTAL
Intervention: Micardis (Telmisartan)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Micardis (Telmisartan) with low-dose aspirin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12207634

Group type: EXPERIMENTAL
Intervention: 7.5 mg methotrexate (MTX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 mg methotrexate (MTX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AUC(24,36 h) >= 700 nmol l(‐1) h
Number of subjects: 24

Group type: COMPARATOR
Intervention: AUC(24,36 h) < 700 nmol l(‐1) h
Number of subjects: 24
Study: 10487104

Group type: EXPERIMENTAL
Intervention: Intensified hygiene with frequent handwashing and educational procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation group (control)
Number of subjects: 0
Study: 8951627

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg 1 x daily for 3 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 1758817

Group type: EXPERIMENTAL
Intervention: MS Contin tablet 200 mg (controlled release morphine sulphate)
Number of subjects: 0
Study: 6138117

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30343313

Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 321

Group type: COMPARATOR
Intervention: 4-5% albumin
Number of subjects: 321
Study: 27199859

Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy (AAT) treatment group (n = 14) participated in twice-weekly 1-hour sessions of AAT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 8) participated in one activity from a range of therapeutic activities that were part of the functional program
Number of subjects: 22
Study: 25344101

Group type: EXPERIMENTAL
Intervention: Baseline decisional uncertainty
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Baseline informed subscale
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Participant demographic and baseline measures
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: State anxiety
Number of subjects: 476
Study: 22206862

Group type: EXPERIMENTAL
Intervention: Socio-demographic factors (area-based deprivation scores)
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: Fathers' occupational social class at birth
Number of subjects: 1559

Group type: COMPARATOR
Intervention: UKALL XI trial participants
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Sex and age at diagnosis
Number of subjects: 1559
Study: 21353111

Group type: COMPARATOR
Intervention: Ibuprofen alone (10 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ibuprofen combined with acetaminophen (10 mg/kg ibuprofen + 15 mg/kg acetaminophen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ibuprofen followed by acetaminophen (10 mg/kg ibuprofen followed by 15 mg/kg acetaminophen 3 hours later)
Number of subjects: 60
Study: 18443566

Group type: EXPERIMENTAL
Intervention: wrist‐HBP (Omron R7 with position sensor)
Number of subjects: 79

Group type: COMPARATOR
Intervention: arm‐HBP (Omron 705IT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: ambulatory BP (ABP, SpaceLabs)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: wrist‐arm HBP difference
Number of subjects: 79
Study: 16754526

Group type: EXPERIMENTAL
Intervention: Limited intervention (one visit with asthma self‐management education and provision of inhaled budesonide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular asthma care manager follow‐up
Number of subjects: 0
Study: 14530005

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting plus transmyocardial laser revascularization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 20
Study: 11168192

Group type: EXPERIMENTAL
Intervention: Oblique lateral cephalometric radiography (OLCR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard horizontal X-ray beam direction
Number of subjects: 16

Group type: COMPARATOR
Intervention: Optimal horizontal X-ray beam direction
Number of subjects: 16
Study: 9289706

Group type: EXPERIMENTAL
Intervention: Obese patients with disturbances in carbohydrate and lipid metabolism
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Obese patients with disturbance in lipid metabolism
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Obese patients with no symptoms of metabolic diseases
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls before fat rich meal
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls after fat rich meal
Number of subjects: 51
Study: 1475671

Group type: EXPERIMENTAL
Intervention: Oral hygiene motivation tool (Parograph)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classic clinical methods (brush-techniques)
Number of subjects: 100
Study: 6228196

Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (13‐cis‐retinoic acid) for four months
Number of subjects: 20
Study: 31273316

Group type: EXPERIMENTAL
Intervention: Assessment of the percentage of the sarcomatoid component
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Assessment of the transitional pattern
Number of subjects: 54
Study: 30239767

Group type: EXPERIMENTAL
Intervention: Early BCG vaccination
Number of subjects: 6583
Study: 28480343

Group type: EXPERIMENTAL
Intervention: Tilted prone with 'Bernoulli maneuver' (B)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard prone (C)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups (C and B)
Number of subjects: 67
Study: 27302514

Group type: EXPERIMENTAL
Intervention: Photon radiation therapy (XRT)
Number of subjects: 35
Study: 24899076

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention plus referral list
Number of subjects: 403

Group type: COMPARATOR
Intervention: Usual care plus referral list
Number of subjects: 403
Study: 21761149

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 19
Study: 19653744

Group type: EXPERIMENTAL
Intervention: Presentation of numerically smaller digit first
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Presentation of letters pairs (e.g., A-Z)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Presentation of mixed digit-letter pairs (e.g., 1-Z)
Number of subjects: 6
Study: 17326881

Group type: EXPERIMENTAL
Intervention: Misoprostol (25 microg intravaginally every 3 h, max 200 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg PGE(2) gel intracervically every 6 h, max three doses in 24 h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 100
Study: 15871365

Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride (Ganaton) 50 mg three times daily for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mosapride citrate 5 mg three times daily for 2 weeks
Number of subjects: 60
Study: 11361191

Group type: EXPERIMENTAL
Intervention: Passive coping style of resting
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Active coping style of transforming pain
Number of subjects: 190

Group type: COMPARATOR
Intervention: Coping styles (both active and passive)
Number of subjects: 190
Study: 9531075

Group type: EXPERIMENTAL
Intervention: Thymostimulin, 70 mg i.m. qd for the first month and every other day thereafter
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Short-term antimicrobial chemoprophylaxis with pefloxacin (800 mg i.v. qd for the first 4 days) and polychemotherapy with teicoplanin (800 mg i.v. qd) and netilmicin (300 mg i.m. qd)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 634

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 634
Study: 7976582

Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2684316

Group type: EXPERIMENTAL
Intervention: Oestrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30741747

Group type: EXPERIMENTAL
Intervention: 40% PPO trial
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exhaustive bouts (84% ± 2% PPO)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RPE during exercise
Number of subjects: 11
Study: 27492276

Group type: EXPERIMENTAL
Intervention: Ischemic compression
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Placebo (sham ischemic compression)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 25511214

Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl added to 0.5% bupivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline mixed with 10 ml of 0.5% bupivacaine
Number of subjects: 64
Study: 23281974

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 40
Study: 20634018

Group type: EXPERIMENTAL
Intervention: Active ITD-7
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham ITD-7
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ITD-7 in prehospital setting
Number of subjects: 81
Study: 19487509

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1226
Study: 18072125

Group type: EXPERIMENTAL
Intervention: 2.5 mg of droperidol (DROP) IM
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 20
Study: 14715050

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (specific drugs not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-potency antipsychotics coadministered with inhibitors such as clarithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies for adverse cardiovascular events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11409662

Group type: EXPERIMENTAL
Intervention: Individualized physical activity advice at baseline and at 3, 6, and 12 months follow-up
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Individualized physical activity advice
Number of subjects: 69
Study: 9861221

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Comparison of SSRIs and TCAs
Number of subjects: 1680
Study: 7809416

Group type: EXPERIMENTAL
Intervention: Rectangular field of view (R‐FOV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Square field of view (S‐FOV)
Number of subjects: 0
Study: 3288683

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg, three doses over 14 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketotifen (200 ng intradermal PAF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 6
Study: 31036048

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) plus intranasal medication
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg) plus intranasal medication
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo plus intranasal medication
Number of subjects: 600
Study: 29110703

Group type: EXPERIMENTAL
Intervention: Movement Coaching (n = 201)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Low intensity control (n = 211)
Number of subjects: 412
Study: 25755233

Group type: EXPERIMENTAL
Intervention: MyAsthma portal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 23180584

Group type: EXPERIMENTAL
Intervention: Helium-hyperoxia (HeHOx)
Number of subjects: 24
Study: 21988668

Group type: EXPERIMENTAL
Intervention: 3-week titration (weekly quarter-dose increments over 3 weeks to full dose [30 µg])
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 6-week titration (biweekly quarter-dose increments over 6 weeks to full dose)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No titration (full dose over 8 weeks)
Number of subjects: 234
Study: 18932010

Group type: EXPERIMENTAL
Intervention: Transoesophageal Doppler monitoring (TDM)
Number of subjects: 127
Study: 16532500

Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m2 intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 170
Study: 12684288

Group type: EXPERIMENTAL
Intervention: High-dose inhaled fluticasone (880 micro g/d) for 28 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14727967

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study: 9689201

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens 0.625 mg/day for 21 days plus chlormadinone 2 mg for the last 12 days (Group I)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oral conjugated estrogens 0.625 mg/day plus chlormadinone 1 mg/day, continuous and uninterrupted (Group II)
Number of subjects: 27
Study: 8126242

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser followed by root planning
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser followed by air‐powder abrasive treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 2671559

Group type: EXPERIMENTAL
Intervention: Daily rifampicin (600 mg), ethionamide (500 mg), and dapsone (100 mg) or clofazimine (100 mg) for 8 weeks followed by once weekly rifampicin (600 mg) and daily ethionamide (500 mg) and dapsone (100 mg) or clofazimine (100 mg) for 44 weeks
Number of subjects: 216
Study: 791442

Group type: EXPERIMENTAL
Intervention: Streptokinase (2,500,000 IU intravenous infusion over 24 hours)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Control group (no streptokinase)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 595

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 595

Group type: COMPARATOR
Intervention: Streptokinase and Control group
Number of subjects: 595
Study: 31665326

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at 67 µg/kg/day for 1 year
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 101
Study: 30676466

Group type: EXPERIMENTAL
Intervention: Parent-targeted and mediated video intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study: 28323541

Group type: EXPERIMENTAL
Intervention: Weak 3D (W3D)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Strong 3D (S3D)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (no 3D technology)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 3D technology (W3D and S3D)
Number of subjects: 105
Study: 25398590

Group type: EXPERIMENTAL
Intervention: Fibrin-sealant-delivered cisplatin chemotherapy (FS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cisplatin hyperthermic intraperitoneal perfusion chemotherapy (CHIC)
Number of subjects: 42
Study: 23664200

Group type: EXPERIMENTAL
Intervention: Zinc and micronutrients (sprinkles)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Micronutrients without zinc (control)
Number of subjects: 143
Study: 21146267

Group type: EXPERIMENTAL
Intervention: Intensive intervention (3 educational seminars, assistance with action plans, monthly monitoring)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard intervention (feedback report, educational materials)
Number of subjects: 77
Study: 18040728

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (III)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (IV)
Number of subjects: 32
Study: 17050042

Group type: EXPERIMENTAL
Intervention: High-titer varicella vaccine (PUVV) - approximately 50,000 PFU
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Lower-titer formulation of VARIVAX - approximately 5400 PFU
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: High-titer varicella vaccine (PUVV)
Number of subjects: 1366
Study: 12624290

Group type: EXPERIMENTAL
Intervention: Lower concentrations of IL-10 (<6 pg/mL)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: IL-10 levels
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: IL-4 levels
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Early worsening
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Neurological worsening
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Eighty-three patients (35.9%)
Number of subjects: 231
Study: 11008922

Group type: EXPERIMENTAL
Intervention: 25,000 IU of retinol daily
Number of subjects: 2297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 2297
Study: 9081107

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (11.4 gm)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Insulin solution (225 IU insulin, glucose with glucose clamp technique, and potassium) in addition to amino acid infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 8382132

Group type: EXPERIMENTAL
Intervention: Dihydralazine (7.5 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Enalaprilat (1.25 mg)
Number of subjects: 22
Study: 31384411

Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (5 g of flaxseed oil containing 2.5 g α‐Linolenic acid)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (200 ml of 1.5% fat milk)
Number of subjects: 44
Study: 30258212

Group type: EXPERIMENTAL
Intervention: Standard treatment plus zoledronic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 60
Study: 27158914

Group type: EXPERIMENTAL
Intervention: B-SAFE intervention
Number of subjects: 615

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 615
Study: 24595547

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504